Metabotype analysis for personalized biology: A new bioanalytical territory for high-resolution MS

Bioanalysis

Volumn 5, Issue 10, 2013, Pages 1149-1152

  Bertrand, Rochat ^a   Amélie, Favre ^b   Pierre Edouard, Sottas ^c  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c BioKaizen   (Switzerland)

Author keywords

biological passport; LC HRMS; metabolomics; metabotyping; personalized medicine

Indexed keywords

GLUCURONOSYLTRANSFERASE; SULFOTRANSFERASE;

CONCENTRATION (PARAMETERS); GENETIC ASSOCIATION; GENETIC TRAIT; HUMAN; HYDROPHILIC INTERACTION CHROMATOGRAPHY; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METABOLITE; METABOLOME; METABOLOMICS; PERSONALIZED MEDICINE; QUADRUPOLE MASS SPECTROMETRY; QUANTITATIVE ANALYSIS; REVIEW; SENSITIVITY ANALYSIS;

BIOLOGICAL MARKERS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; INDIVIDUALIZED MEDICINE; MASS SPECTROMETRY; METABOLOMICS;

EID: 84878507632     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.13.79     Document Type: Review

References (20)

1. Psychogios N, Hau DD, Peng J et al. The human serum metabolome. PLoS One 6, e16957 (2011).
2. Joyner MJ, Pedersen BK. Ten questions about systems biology. J. Physiol. 589, 1017-30 (2011).
3. Henry H, Sobhi HR, Scheibner O, Bromirski M, Nimkar SB, Rochat B. Comparison between a high-resolution single-stage Orbitrap and a triple quadrupole mass spectrometer for quantitative analyses of drugs. Rapid Commun. Mass Spectrom. 26, 499-509 (2012).
4. Ramanathan R, Korfmacher W. The emergence of high-resolution MS as the premier analytical tool in the pharmaceutical bioanalysis arena. Bioanalysis 4, 467-469 (2012).
5. Rochat B, Kottelat E, McMullen J. The future key role of LC-high-resolution-MS analyses in clinical laboratories: a focus on quantifcation. Bioanalysis 4, 2939-2958 (2012).
6. Dunn WB, Broadhurst D, Begley P et al. Human serum metabolome (HUSERMET) consortium. Procedures for large-scale metabolic profling of serum and plasma using gas chromatography and liquid chromatography coupled to mass spectrometry. Nat. Protoc. 6, 1060-1083 (2011).
7. Yuan M, Breitkopf SB, Yang X, Asara JM. A positive/negative ion-switching, targeted mass spectrometry-based metabolomics platform for bodily fuids, cells, and fresh and fxed tissue. Nat. Protoc. 7, 872-881 (2012).
8. Vuckovic D. Current trends and challenges in sample preparation for global metabolomics using liquid chromatography-mass spectrometry. Anal. Bioanal. Chem. 403, 1523-1548 (2012).
9. Gika HG, Theodoridis GA, Vrhovsek U, Mattivi F. Quantitative profling of polar primary metabolites using hydrophilic interaction ultrahigh performance liquid chromatography-tandem mass spectrometry. J. Chromatogr. A 1259, 121-127 (2012).
10. Dumlao DS, Buczynski MW, Norris PC, Harkewicz R, Dennis EA. High-throughput lipidomic analysis of fatty acid derived eicosanoids and N-acylethanolamines. Biochim. Biophys. Acta. 1811, 724-736 (2011).
11. Nicholls AW. Realising the potential of metabolomics. Bioanalysis 4, 2195-2197 (2012).
12. Dunn WB, Broadhurst D, Brown M et al. Metabolic profling of serum using ultra performance liquid chromatography and the LTQ-Orbitrap mass spectrometry system. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 871, 288-98 (2008).
13. Nicholson G, Rantalainen M, Maher AD et al. Human metabolic profles are stably controlled by genetic and environmental variation. Mol. Syst. Biol. 7, 525 (2011).
14. Plebani M, Lippi G. Personalized (laboratory) medicine: a bridge to the future. Clin. Chem. Lab. Med. 6, 1-4 (2013).
15. Sottas PE, Kapke GF, Vesterqvist O, Leroux JM. Patient-specifc measures of a biomarker for the generation of individual reference intervals: hemoglobin as example. Transl. Res. 158, 360-368 (2011).
16. Sottas PE, Vernec A. Current implementation and future of the Athlete Biological Passport. Bioanalysis 4, 1645-1652 (2012).
17. Sottas PE, Kapke GF, Leroux JM. Adaptive bayesian approach to clinical trial renal impairment biomarker signal from urea and creatinine. Int. J. Biol. Sci. 9, 156-163 (2013).
18. Adamski J, Suhre K. Metabolomics platforms for genome wide association studies-linking the genome to the metabolome. Curr. Opin. Biotechnol. 24, 39-47 (2013).
19. Suhre K, Shin SY, Petersen AK et al. Human metabolic individuality in biomedical and pharmaceutical research. Nature 477, 54-60 (2011).
20. Bellcross CA, Page PZ, Meaney-Delman D. Direct-to-consumer personal genome testing and cancer risk prediction. Cancer J. 18, 293-302 (2012).